Summary
In this study we have evaluated the reliability of a fluorescence-based method used for rapid identification of irreversible CYP inhibitors (mechanism-based inhibitors). This was accomplished by comparing the time-dependence pattern of IC50 values from fluorometric kinetic measurements. For irreversible CYP inhibitors, IC50 values decreased as incubation proceeded. This was due to progressive inactivation of corresponding enzymes by reactive metabolites generated during the incubation. This change pattern was confirmed using a number of known irreversible CYP inhibitors, including furafylline, midazolam, erythromycin, clarithromycin, oleandomycin, 17α-ethynylestradiol and verapamil. The pattern was different in reversible inhibition, depending upon the compounds tested in the fluorometric kinetic assay. For some compounds, such as clotrimazole, IC50 values remained relatively stable, whereas other compounds, such as miconazole, terfenadine and ketoconazole showed a significant increase with incubation time. Monitoring tested compounds by LC-MS/MS during the incubation confirmed that increases of IC50 were probably caused by the loss of inhibitors, resulting from either metabolic degradation, or non-specific binding to microsomal proteins.
Similar content being viewed by others
References
von Moltke L.L; Greenblatt D J; Duan S X; Harmatz J S; Shader R I In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharm. (1994), 34 (12), 1222–1227.
Griffin J.P. The withdrawal of mibefradil (Posicor). Adverse Drug Reactions and Toxicological Reviews (1998), 17(2–3), 59–60.
Lin, J. H.; Lu, A. Y. H., Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. (1998), 35(5), 361–390.
Yan Z.; Caldwell G. W. Metabolism profilling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. (2001), 1(5), 403–425.
Chu, I.; Favreau, L.; Soares, T.; Lin, C.C.; Nomeir, A.A. Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes. Rapid Comm. in Mass Spectr. (2000), 14(4), 207–214.
Crespi, C. L.; Stresser, D. M. Fluorometric screening for metabolismbased drug-drug interactions. J. Pharm. Toxicol. Methods (2001), 44(1), 325–331.
Crespi, C. L.; Miller, V. P.; Penman, B. W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. (1997), 248(1), 188–190.
Palamanda, J.R.; Casciano, C.N.; Norton, L.A.; Clement, R.P.; Favreau, L.; Lin, C-C.; Nomeir, A.A. Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazineyl] pyrimidine. Drug Metab. Despos. (2001), 29(6), 863–867.
Racha, J.K.; Rettie, A.E.; Kunze, K.L. Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry (1998), 37(20), 7407–7419.
Silverman, R.B. Mechanism-based Enzyme Inactivation: Chemistry and Enzymology (vol. 1) CRC Press, Inc., 1988.
Bennett, M.; Prueksaritanont, T.; Lin, J.H. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. (2000), 28(2), 125–130.
Khan, K.K.; He, Y.Q.; Domanski, T.L.; Halpert, J.R. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mole. Pharm. (2002), 61(3), 495–506.
Zhang, W.; Ramamoorthy, Y.; Kilicarslan, T.; Nolte, H.; Tyndale, R.F.; Sellers, E.M. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab. Dispos. (2002), 30(3), 314–318.
Yun, C. H.; Okerholm, R. A.; Guengerich, F.P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos. (1993) 21(3), 403–9.
Obach, R. Scott. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab. Dispos. (1997), 25(12), 1359–1369.
Lindstrom, T.D.; Hanssen, B.R.; Wrighton, S.A. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob. Agents Chemother (1993), 37(2), 265–269.
Sutton D; Butler A M; Nadin L; Murray M Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J. Pharm. Exp. Ther. (1997), 282(1), 294–300.
Bapiro, T. E.; Egnell, A-C; Hasler, J. A.; Masimirembwa, C. M. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450S. Drug Metab. Dispos. (2001), 29(1), 30–35.
Gibbs, Megan A.; Thummel, Kenneth E.; Shen, Danny D.; Kunze, Kent L. Inhibition of cytochrome P-4503A (CYP3A) in human intestinal and liver microsomes: comparison of KI values and impact of CYP3A5 expression. Drug Metab. Dispos. (1999), 27(2), 180–187.
Jacobsen, W.; Kirchner, G.; Hallensleben, K.; Mancinelli, L.; Deters, M.; Hackbarth, I.; Benet, L.Z.; Sewing, K-F.; Christians, U. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab. Dispos. (1999), 27(2), 173–179.
Bachus R; Bickel U; Thomsen T; Roots I; Kewitz H The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics (1999), 9(6), 661–668.
Bourrie, M.; Meunier, V.; Berger, Y.; Fabre, G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. (1996), 277(1), 321–32.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yan, Z., Rafferty, B., Caldwell, G.W. et al. Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses. Eur. J. Drug Metab. Pharmacokinet. 27, 281–287 (2002). https://doi.org/10.1007/BF03192339
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03192339